FilingSEC EDGAR8-K
X4 Pharmaceuticals Reaches Agreement with FDA on Phase 3 Trial Sample Size
· SEC accepted
StagePhase 3
Filing content
X4 Pharmaceuticals announced that the FDA agreed to a reduction in the sample size for its global 4WARD Phase 3 clinical trial from 176 to 126 participants.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…